Navigation Links
Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Date:9/5/2007

FREEPORT, N.Y., Sept. 5 /PRNewswire/ -- AGI Dermatics, the bio- pharmaceutical laboratory that pioneered DNA research for skincare, announced today that U.S. Food & Drug Administration (FDA) has granted Fast Track designation for Dimericine (T4N5) for treatment of solar and ultraviolet photosensitivity in patients with Xeroderma Pigmentosum (XP). Dimericine, also known as T4N5 Liposome Lotion, is a topical drug developed by AGI currently in clinical trials for treating XP patients with skin cancers and pre-cancers.

"Dimericine is the result of decades of research into DNA repair and its potential to prevent skin cancer and photodamage caused by UV radiation," said Daniel Yarosh, Ph.D., President and CEO of AGI Dermatics. "We are optimistic that this Fast Track designation will accelerate our efforts to bring to market a treatment option for the thousands of people who suffer from the life-threatening disease XP."

Xeroderma pigmentosum, or XP, is a rare genetic disorder that blocks the body's natural ability to repair DNA damage caused by ultraviolet (UV) light. Minimal exposure to UV light in XP patients results in persistent DNA damage and causes severe sunburn, blistering, irregular dark spots and a 1000-fold increased risk of skin cancer. People with severe XP often need to avoid sunlight completely. Half of these patients develop skin cancers by the age of 8 and their life expectancy is shortened by 30 years.

Fast Track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life- threatening conditions and that demonstrate the potential to address unmet medical needs. It grants accelerated review for all steps of the process, including the applications related to clinical developments and may reduce the time required to bring the drug to market. With this designation, the FDA has acknowledged XP as a serious or life threatening disease and has also determined there is no drug currently marketed for treatment of XP.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... , ... February 19, 2020 , ... The Team Type ... access to medicine for everyone affected by diabetes, announced a partnership with VeloCity, a ... , The third annual VeloCity event takes place on May 2nd and begins on ...
(Date:2/19/2020)... ... February 19, 2020 , ... The swine flu (H1N1) was ... disease (FMD) is a potential new outbreak. Although the U.S. has eradicated this ... than two-thirds of countries in the world, posing a risk from trading partners. ...
(Date:2/15/2020)... ... February 14, 2020 , ... ... "oral-systemic” link between the organisms that cause inflammatory gum disease (e.g., periodontitis) and ... ProBiora Health?? , offers new tools in the fight against common dental problems ...
Breaking Medicine Technology:
(Date:2/20/2020)... (PRWEB) , ... February 20, 2020 , ... R3 Medical ... Las Vegas Nevada. Providers will learn how to perform injections for all large and ... not easy to learn from online videos. The best opportunity is to perform injections ...
(Date:2/20/2020)... CLARA, Calif. (PRWEB) , ... February 20, 2020 ... ... for insurance agents, has a new release with next generation API integration ... , Launched by VisitorsCoverage Inc. in 2017, TMQuotes was the first ...
(Date:2/19/2020)... ... February 19, 2020 , ... The American ... for its new Lifestyle Medicine Residency Curriculum (LMRC). The curriculum is the first ... residency programs. Driven by resident involvement, the curriculum has included residents in ...
(Date:2/19/2020)... ... , ... In 2017, the EU’s revamped Medical Device Regulation ... govern medical device manufacturers under the Medical Devices Directive (MDD); the timeline provided ... from the previous MDD include:, , Elimination of the ...
(Date:2/19/2020)... ... ... SEAL SHIELD, LLC - Almost a hundred thousand people are dying in the ... for Disease Control (CDC), 80% of infections are transmitted by hands. But what hasn’t ... an extension of people’s hands, but not getting cleaned nearly as often, if ever. ...
Breaking Medicine News(10 mins):